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1. INTRODUCTION AND 
REVIEW OF LITERATURE
1.1  Introduction of rectal carcinoma
 Colorectal carcinoma is a common cancer all over the world. 
Colorectal cancer ranks second in terms of both incidence & mortality 
in more developed countries. Nearly 945,000 new colo-rectal cancers 
cases are diagnosed world wide each year and colo-rectal cancer is 
responsible for some 492,000 deaths. There is significant geographical 
variation in age standardized incidence as well as in cumulative 0-74 
years  incidence,  high rates occurring in countries  of  Europe,  North 
America,  Australia  and  Japan  (Bernard  W.  et  al  2003).  For 
carcinoma rectum, the crude incidence rate per 100,000 populations in 
Chennai, India and world for males are 3.0, 3.6, & 16.4 respectively 
and  for  females  are  1.6,  2.6  and  14.8  respectively.  The  age 
standardized rates per 100,000 population in Chennai, India and world 
for males are 3.7, 4.7, and 19% respectively and for females are 1.9, 
3.2 and 14.4 respectively (GLOBOCAN 2000, IARC). Geographic 
variation in colorectal cancer incidence implies and to a large extent 
proves the critical nature of environmental factors. The incidence rate 
for residents of Alaskan natives exceeds to 70 per 100,000 (Brown 
MO et al, 1998), whereas that far residents of Gambia and Algeria is 
less than 2 per 100,000 (Parkin, DM et al, 1999).
The  etiology  of  colorectal  cancer  is  complex  involving  an 
interplay  of  environmental  and  genetic  factors.  Familial  factors 
contribute to the risk of sporadic colorectal cancer. Involvement of at 
least one first degree relative with colorectal cancer doubles the risk of 
colorectal  cancer  (Fuchs  CS et  al,  NEJM 1994).  There  is  further 
enhancement of the risk if such a relative is affected before the age of 
60yrs. Obesity and total caloric intakes are independent risk factors for 
rectal  cancer  (Singh  PN  et  al,  1998).  Ingestion  of  red  meat  is 
associated  with  an  increased  risk  of  colorectal  cancer.  Fried, 
barbecued and processed meats are associated with rectal cancer, with 
an odds ratio of 6 (Chan J. et al, 1998). 
Vegetable, fruits and calcium has been implicated as having a 
protective effect on colorectal cancer development. A sedentary life 
style may account for an increased colorectal cancer risk. Association 
between alcohol  consumption  in  men  and risk  of  rectal  cancer  are 
strongest.  Perhaps  interference  with  foliate  metabolism  through 
acetaldehyde is responsible (Seitz HK et al, 1990). There is an inverse 
relationship between use of aspirin, NSAID and the incidence of both 
colorectal cancer and adenomas. In a cohort study, the relative risk of 
colorectal cancer was 0.49 (95% confidence interval, 0.24 to 1.0) for 
regular  NSAID users  compared  with  non users  (Smalley  W et  al, 
1999). Familial syndromes associated with increased risk of colorectal 
cancer  are  FAP,  HNPCC,  and  Peutz  Jeghers  syndrome,  familial 
colorectal cancer syndrome.
The major malignant histologic type is adenocarcinoma. Other 
less  common  epithelial  tumour  types  include  mucinous 
adenocarcinoma,  signet  ring  carcinoma,  squamous  cell  carcinomas, 
adenosquamous carcinomas and undifferentiated carcinomas.
The college of American pathologists has published an expert 
panel consensus statement outlining its interpretation of the validity 
and  usefulness  of  a  large  number  of  putatively  prognostic  and 
predictive factors in colorectal carcinoma (Compton CC et al, 2000). 
Variables were categorized as belonging to categories I through IV. 
The categories are defined as:
Category I :  Those  factors  proven  to  be  of  prognostic 
importance  based  on  evidence  from  multiple  statistically  robust, 
published trials and generally used in patient management.
Category 1 factors are the T, N, and M categories of the current 
AJCC-UICC  staging  system,  blood  or  lymphatic  vessel  invasion, 
residual tumor after surgery with curative intent (the R category), an 
elevation of the preoperative CEA level.
Category II A : Factors intensively studied biologically or 
clinically as both and repeatedly shown to have prognostic value for 
outcome  or  predictive  value  for  therapy  that  is  of  sufficient 
importance warrant inclusion in the pathology report but that remain 
to be validated in statistically robust studies. Factors in category IIA 
included tumor grade, radial margin status (for resection of specimens 
with nonperitonealized surfaces), and residual tumor in the resection 
specimen after neo-adjuvant therapy. 
Category II B : Factors shown to be promising in multiple 
studies  but  for  which  sufficient  data  are  lacking  for  inclusion  in 
category I or IIA. Factors in category IIB included histologic type, 
histologic features associated with MSI (i.e., host lymphoid response 
to tumor and medullary or mucinous histologic type), high degree of 
MSI (MSI-H), loss of heterozygosity (LOH) of 18q (DCC gene loss), 
and tumor border configuration (infiltrating vs. pushing border). 
Category III :  Factors  felt  to  be  not  yet  sufficiently 
studied  to  determine  their  prognostic  value.  Factors  grouped  in 
category III included the following: DNA content, all other molecular 
markers  except  LOH of  18q/DCC and MSI-H,  perineural  invasion, 
microvessel density, tumor cell–associated proteins or carbohydrates, 
peritumoral  fibrosis,  peritumoral  inflammatory  response,  focal 
neuroendocrine  differentiation,  nuclear  organizing  regions,  and 
proliferation. 
Category IV : Factors that have been adequately studied 
and  have  convincingly  shown  no  prognostic  significance.  Those 
factors  included  in  category  IV  (proven  to  be  of  no  significance) 
include tumor size and gross tumor configuration. 
1.2 Cell Cycle: Cell cycle is comprised of four phases G1 (Gap 1), 
S (DNA synthesis), G2 (Gap 2) and M (Mitotic).
Details of Cell Cycle: 
FIGURE 1
To summarize,  three  partially  redundant  D-type  cyclins  (D1, 
D2, and D3) activate two partially redundant cdks (cdk4 and cdk6). 
Although, unlike most other cyclins, D-type cyclins do not appear to 
be  expressed  with  high  periodicity  in  cycling  cells,  the  interval  at 
which their primary activating function is thought to occur is from mid 
to late G1 to direct phosphorylation of the cell-cycle inhibitor pRb and 
related proteins p107 and p130. Phosphorylation of these proteins by 
cyclin  D–cdk4/6  inactivates  their  negative  regulatory  functions, 
allowing  progression  into  S  phase.  Unlike  D-type  cyclins,  E-type 
cyclins (E1 and E2) are  expressed with high cell-cycle  periodicity, 
accumulating in late G1 and declining during S phase. E-type cyclins 
activate  cdk2,  and the  fact  that  premature  expression  of  cyclin  E1 
leads to accelerated entry into S phase has suggested that the target(s) 
must  be  proteins  responsible  for  initiation  of  DNA  replication. 
However, the essentiality of cyclin E–cdk2 in this context has been 
put into question by the demonstration that cells from cyclin E1/E2 
nullizygous mouse embryos can cycle with reasonably normal kinetics 
and  can  certainly  initiate  DNA  replication.  The  most  likely 
explanation  for  the  dispensability  of  E-type  cyclins  for  S-phase 
functions is redundancy with cyclin A, which also activates cdk2. 
Cyclin A accumulates initially at the G1/S-phase boundary and 
persists until prometaphase of mitosis. It has been best characterized 
as an activator of cdk2; however, it has also been reported to form 
complexes with cdk1. It is presumed that cdk2, activated by E-type 
cyclins and cyclin A, promotes cell-cycle progression from the G1-S 
boundary through the G2 interval. 
At  this  time,  B-type  cyclins,  in  conjunction  with  cdk1,  are 
responsible  for  getting  cells  into  and  through  mitosis.  Although 
mammalian cells express a number of B-type cyclins, only cyclin B1 
appears to be essential. Cyclin B1 accumulates through S phase and 
G2 and  then  is  degraded  at  the  metaphase-anaphase  transition.  It 
should  be  pointed  out  that  the  cdk  family  is  extensive  and  that 
eukaryotes possess many additional cdks that ostensibly has nothing to 
do with cell-cycle regulation. 
1.21 Cyclin Dependent Kinases:
The major transitions of the eukaryotic cell cycle are triggered 
by a family of serine threonine kinases called the Cyclin Dependent 
Kinases (CDKS). At least nine CDKs  (CDK 1-9) are known so far 
(Morgan, etal 1997). CDK activation required the regulatory subunit 
called the cyclins and phosphorylation of a conserved threonine by the 
CDK  activating kinase  (CAK)  which  itself  is  a  complex  of  a 
regulatory cyclin H and catalytic CDK 7 subunit.
The typical CDK catalytic unit contains 300 amino acids. The 
catalytic  subunit  is  completely  inactive  when  it  is  monomeric  and 
unphosphorylated. Cyclins are the primary regulators of the CDKs.
CDK1 constitute the homologous 34 KDa  products encoded by 
the yeast cell division cycle (cdc) genes. p34 cdc2 (CDK1) is a highly 
conserved cyclin associated  34 KDa  protein  kinase  that  becomes 
activated on phosphorylation. Complexed with cyclin B it forms the 
maturation promoting factor (MPF). Without p34 cdc2 the cells are 
unable to divide (Hamaguchi et al, 1992), p34 cdc2 distribution is 
cytoplasmic  during  the  interphase,  shifts  into  the  nucleus  at  the 
beginning of prophase and extends throughout the cell in the mitotic 
phase (Bailly et al, 1989, Doussis et al, 1994). As key regulators of 
the cell cycle, the activity of cyclin dependent kinases is controlled by 
four  highly  conserved  biochemical  mechanisms  forming  a  web  of 
regulatory pathways mismatched in this elegance and intricacy.
Cyclins are a class of structurally related proteins that bind and 
activate the catalytic subunit of the CDKS. To date there are eight type 
of cyclins, (cyclins A to H) and all of them share an 150 amino acid 
region of homology call the cyclin box which is responsible for the 
CDK  binding  and  activation  (Hunt  et  al  1991).  Cyclins  can  be 
roughly divided into two subfamilies, the G1 cyclins and the mitotic 
cyclins.  The  G1  cyclins  (C,  D,  E)  are  short  lived  and  have  rapid 
turnover throughout cell cycle. Their levels are determined by levels 
of  transcription of their mRNA. The mitotic cyclins (A, B) are very 
stable throughout the interphase but undergo rapid proteolysis by an 
ubiquitin dependent pathway during mitosis, compared to the mitotic 
cyclins the G1 cyclins have a longer C terminal sequence at the cyclin 
box and it is this part of the protein that seems to confer instability to 
the  G1  cyclins  (Glotzer  et  al,  1991).  The  function  of  cyclins  is 
primarily controlled by changes in the cyclin levels which increase at 
specific stages and are often categorized by the stage at which they are 
expressed. The transcription of the mitotic cyclins, cyclin A and B are 
cell  cycle  dependent  and  their  levels  are  determined  both  by 
transcription  and  proteolysis  (Hunter  et  al,  1992,  Minshull  et  al, 
1990). Protein degradation is an effective  method for  promoting in 
unidirectional  cell  cycle  transitions  because  of  its  rapidity  and 
irreversibility. Three major cell cycle transitions, entry into S phase, 
separation  of  sister  chromatids  and  exit  from  mitosis,  require  the 
degradation  of  specific  proteins  via  the  ubiqutination  by  26  S 
proteosome pathway.
The  degradation  of  mitotic  cyclins  involves  the  ubiquitin 
dependent proteolytic machinery and a small  sequence motif  called 
the destruction box located at the N terminus. This region has a small 
cluster  of  conserved  residues  followed  by  lysine  rich  stretch.  The 
destruction box region differs between cyclin A and B and probably 
accounts for the finding that in mitosis cyclin A is degraded before 
cyclin B.
G1  cyclins  lack  the  mitotic  destruction  box  but  contain  the 
PEST  sequences  as  the  peptide  motifs  that  are  important  for 
proteolysis. PEST sequences (rich in proline, glutamic acid, serine and 
threonine)  are  frequency  present  in  unstable  proteins  such  as  G, 
cyclins  and  contain  specific  sites  of  phosphorylation. 
Phosphorylations of PEST regions facilitate the destructions of PEST 
sequence proteins. It is not the PEST sequences per se but the specific 
motifs  within  them  that  actually  control  the  PEST  sequence 
recognition by the ubiquitination machinery (Rechsteiner and Rogers 
et al, 1996).
Cyclins are thought to target the CDK to specific substrate and 
sub cellular locations. Cyclin expression varies during cell cycle and 
the periodic expression of different cyclins defines the start of each 
phase  of  the cell  cycle  and also  marks  the  transitions  between the 
various  phases.  Cyclins  and  their  cognate  CDK  catalytic  subunits 
noncovalently form 1:1 complexes to produce the CDK holoenzyme. 
Specific CDKs operate in distinct phases of cell cycles.
TABLE 1: CYCLINS AND CELL CYCLE PHASES
CYCLIN CELL CYCLE PHASE
Cyclin D1 Early G1 phase
Cyclin E G1 / S tansition
Cyclin A S phase
Cyclin B G2 / M phase
1.22 Cyclin D:
The first groups of cyclins that is expressed after the cells are 
stimulated to enter the cell cycle are the cyclin D. these act as growth 
factor sensors. Cyclin D has a relatively short half life of 20 minutes 
approximately and rapidly disappears with the removal of mitogenic 
stimuli  as  the addition of  antiproliferative agents (Peter  SG, 1994). 
Cyclin D helps in moving G0 cells into G1 and early G1 cells into the 
G1 / S transitions in response to the extracellular stimuli.
The D type  cyclins  belong to a  distinct  subset  within  cyclin 
family  based  on  structural  and  functional  criteria.  There  are  three 
genes identified under the family, Cyclin D1, D2 and D3 (Inaba et al, 
1992, Xiong et al, 1992a)
TABLE 2: TYPES OF CYLIN D
1.23 Cyclin E: 
After cyclin D induction, but well before the onset of S phase, 
cyclin E is transcriptionally induced and forms an active complex with 
CDK2. Cyclin E is essential for the cells to enter S phase. Cyclin E 
mRNA  of  and  protein  levels  and  the  activity  of  cyclin  E  -CDK2 
complex, all peak at the G1 / S transition sharply declining as cells 
progresses  through mid  and late  S  phase  (Guadagno et  al,  1993). 
When cyclin E is over expressed, the cells progress through G1 into S 
phase at a faster rate (Ohtsubo et al, 1993). Cyclin E shares some of 
the characteristics with cyclin A which regulate cells once they have 
entered the S phase. Both cyclin E and A in conjunction with CDK2 
associate with pRB related proteins p107 and transcription factor E2F.
Over expression of cyclin E shortens the G1 phase, decreases 
cell size and diminishes the serum requirement for the G1 to S phase 
transition.  Cyclin E activity  gets  down regulated as the cells  reach 
senescence due to the induction of a family of inhibitory proteins that 
inactivate cyclin-CDK complexes. Cyclin E is deregulated in human 
cancers with amplification of cyclin E gene, common in gastric and 
colorectal cancers (Keyomarsi et al, 1997).
1.24 Cyclin A: 
Cyclin A is induced shortly after cyclin E. Cyclin A binds and 
activates CDK2 in S phase and CDK1 in G2 and M phase. A complex 
of CDK2 and cyclin A is required for the cells to progress through S 
phase  and complex  of  CDK1 and cyclin  B is  required  for  mitosis 
(Sherr, et al 1996).
Cyclin  A  has  been  implicated  in  regulation  of  both  DNA 
replication (Wang et al, 1992) and mitosis.  There are two types of 
cyclin A,  A1 and A2 and it  appears that  cyclin A1 is restricted to 
meiosis (Minshull J. et al, 1990). Cyclin A2 binds to both CDK1 and 
CDK2 in a cell cycle dependent manner. Cyclin A2 synthesis begins 
as cells enter S phase and at this point it is exclusively associated with 
CDK2 (Tsai et al,  1991).  Cyclin A CDK2 complex is required for 
DNA replication though not for G1 to S transition. Cyclin A CDK2 is 
required for progression through S phase.
Cyclin A / CDK2 has the important function of histone 
phosphorylation.  One  of  the  events  required  for  cyclin  A 
transcription is a signal from surface adhesion molecule in either 
late G1 or very early S phase. Once cells progress into late G2 
phase, cyclin A2 becomes associated with CDK1 (Pagano et al, 
1992).  The  exact  roles  of  cyclin  A  -  CDK1  complex  versus 
cyclin A - CDK2 has not been defined. One potential role for 
cyclin  A  -  CDK1  /  CDK2  in  late  G2  phase  is  in  the  re-
organisation  of  the  cytoskeleton  in  preparation  for  mitosis 
(Verdeet et al, 1992).
1.25 Cyclin B: 
B type cyclins are necessary for the activation of the cdc2 
kinase at the onset of mitosis. Cyclin B degradation is required 
for the inactivation of the H1 kinase in late mitosis. Cyclin B first 
forms an inactive complex with CDK1 (cdc2) on such a complex 
called pre-MPF (Maturation Promoting Factor) is activated by a 
post translational modification at the onset of mitosis. While the 
rate of cyclin B synthesis during cell cycle is linear, activation of 
MPF at G2/M transition is exponential suggesting that cyclin B 
accumulation alone does not trigger the initiation of mitosis. The 
levels  of  tyrosine  phophorylation  vary  during  the  cell  cycle 
increasing  from  G1  and  G2  and  disappearing  during  mitosis 
coincident with activation of the H1 kinase (Draetta et al, 1988). 
During interphase, CDK1 (cdc2) and cyclin B associate and are 
readily  phosphorylated  on  Thr-14,  tyr-15  and  Thr-161.  This 
inactive pre-MPF accumulates during S and G2 phases of the cell 
cycle. Dephosphorylation of CDK1 (cdc2) on Thr-14 and Tyr-15 
is the rate limiting step controlling entry into mitosis.
After  dephosphorylation  of  these  residues,  the  cdc2-cyclin  B 
complex  becomes  active  and  mitosis  can  start.  Ubiquitination  and 
subsequent degradation of cyclin B brings about the inactivation of 
MPF  which  is  necessary  for  exiting  from  mitosis.  After 
dephosphorylation  of  Thr-161  which  probably  occurs  after  cyclin 
degradation,  monomeric  unphosphorylated  CDK1  (cdc2)  is  formed 
and the cell cycle can restart.
In contrast to cyclin A, cyclin B only associated with CDK1 and 
these  complexes  are  the  mitotic  specific  kinases.  The  sub  cellular 
location of the cyclin B complexes is also cell cycle regulated. During 
S phase and G2 phases the complexes accumulate in the cytoplasm, 
becoming  associated  with  the  centrosomes  late  in  the  interphase 
(Pines et al, 1991). Once the cells reach mitosis complexes move into 
the nucleus. The cyclin B- CDK1 complexes enter the nucleus at the 
beginning of the prophase, before the nuclear envelope breaks down 
and serves as the protein kinase responsible for the phosphorylation 
and consequent dissolution of the nuclear lamina (Peter et al, 1990). 
Inside the nucleus, the cyclin B 1-CDK1 becomes associated with the 
spindle especially the spindle caps and main spindle fibers. Cyclin B1 
has profound effects on the microtubules (Verde et al, 1992) but their 
exact role in organizing the spindle is yet to be defined (Karsenti et 
al, 1991). The activity of cyclin B1-CDK1 complexes is negatively 
regulated  by  phosphorylation  on  the  threonine  14  and  tyrosine  15 
residues  in  the ATP binding region of  the CDK1 promoted by the 
weel and mik 1 protein kinase. In order for the cell to enter mitosis, 
the  cyclin  B1-  CDK1  complexes  are  activated  by  CDC  25 
phosphatase.
In this study the expression of cyclin A is assessed in normal 
rectal  mucosa,  rectal  carcinoma  and  to  assess  the  prognostic 
/predictive value of cyclin A over expression in rectal carcinoma.
1.3 Review Of Literature
Bondi J, et al ; Deregulation of cell cycle control is a hallmark 
of cancer. The primary cyclins (A, B1, D1, D3, and E) are crucial for 
cell  cycle  progression.  Secondary  cyclins  (C and H)  have  putative 
indirect effects on cell cycle progression and have not previously been 
evaluated  in  colon  cancer.  This  study  examined  cyclin  protein 
expression and gene amplification in colon adenocarcinoma and the 
correlation  with  patient  outcome.   Immunohistochemistry  and  real 
time quantitative polymerase chain reaction were used to determine 
cyclin expression and gene amplification in 219 tumours.  RESULTS: 
Cyclin H was overexpressed in all tumours, cyclin C in 88%, cyclin 
B1 in 58%, cyclin A in 83%, cyclin D3 in 36%, cyclin E in 25%, and 
cyclin D1 in 11% of the tumours. Extra gene copies of cyclin A were 
seen in 6.2% of the tumours, cyclin B1 in 9%, cyclin C in 26.9%, 
cyclin D1 in 55%, cyclin D3 in 20.5%, cyclin E in 19.1%, and cyclin 
H in 5.1%. A significant correlation between protein overexpression 
and gene amplification was seen for cyclin C only.  High expression 
of  cyclin  A was  independently  associated  with  improved survival. 
Amplification  of  cyclin  C  was  independently  associated  with  an 
unfavourable prognosis. 
Nozoe T, et,al. Immunohistochemical staining for cyclin A was 
performed for 167 colorectal carcinomas and the correlation between 
cyclin  A expression  and  the  clinicopathological  characteristics  was 
analyzed. One hundred and two carcinomas  (61.1%) had cyclin A 
expression and the other 65 (38.9%) did not. The mean size of the 
tumors with cyclin A expression was significantly larger than that of 
tumors without cyclin A expression (p = 0.012). Survival in patients 
with cyclin A-expressing carcinomas was significantly worse than that 
in patients with carcinomas without cyclin A expression (p = 0.004). 
Cyclin A expression (p = 0.030), as well as lymph node metastasis (p 
= 0.007) and Dukes' stage of the tumors (p < 0.0001) were found to be 
factors  independently  associated  with  unfavorable  prognosis  in 
patients  with  colorectal  carcinoma.  Our  results  demonstrated  that  
immunohistochemical  expression  of  cyclin  A  is  an  independent  
prognostic indicator in patients with colorectal carcinoma.
Li  JQ,  et,al.  To  clarify  the  role  of  cyclin  A  in  multistage 
colorectal  neoplasms,  cyclin  A,  CDK2,  and  Ki67  were 
immunohistochemically stained in 22 normal mucosa, 9 hyperplastic 
polyps,  61  adenomas,  197  primary  carcinomas,  21  lymph  node 
metastases,  and  10  hepatic  metastases.  To  clarify  the  alteration  of 
p27(kip1) during lymphatic invasion, p27(kip1) was also stained in 21 
primary cancers and paired lymph node foci. Situated in nuclei, cyclin 
A  expression  gradually  increased  from  mild  through  moderate  to 
severe  dysplasia  in  adenomas  and  from  normal  tissue  through 
hyperplasia  to  adenoma  to  early  carcinoma.  Expression  was 
significantly decreased in the hepatic metastases and in the primary 
cancers  showing  venous  invasion,  deep  infiltration,  lymph  node 
metastasis,  mucinous  type,  advanced  stage,  or  short  postoperative 
survival  time.   Lymph  node  metastases  lost  more  p27(kip1)  than 
primary foci and hepatic lesions. Thus, dysregulation of cyclin A and  
its control mechanisms may contribute to colorectal carcinogenesis;  
abatement of overexpression of cyclin A is associated with hepatic  
metastasis and cancerous invasion. Loss of p27(kip1) may promote 
lymph node metastasis. 
Palozza  P,  et,al; The  present  study  demonstrates  that  beta-
carotene,  a  natural  pigment  widely  present  in  fruit  and vegetables, 
inhibits the growth of several human colon adenocarcinoma cell lines 
(COLO 320 HSR, LS-174, HT-29 and WiDr) by inducing cell cycle 
arrest  in  G(2)/M phase  and apoptosis.  At  inhibitory  concentrations 
beta-carotene reduced the expression of cyclin A, a key regulator of 
G(2)/M  progression.  Neither  p21  nor  p27,  two  cyclin  kinase 
inhibitors, were significantly modified by carotenoid treatment. This 
study  represents  a  novel  aspect  of  the  biological  profile  of  beta-
carotene  and  a  new  step  in  elucidating  the  underlying  molecular 
mechanisms  of  its  antitumor  action.  In  addition,  since  cell  growth 
inhibitory  effects  were  reached  at  beta-carotene  concentrations 
achievable in vivo following its supplementation, this study provides a 
rational approach for the use of beta-carotene in colon cancer.
Habermann J, et,al; Ulcerative colitis patients are at increased 
risk for developing colorectal carcinomas. Two patient groups were 
selected:  group  A  comprised  8  patients  with  ulcerative  colitis-
associated  colorectal  carcinomas,  group  B  comprised  16  ulcerative 
colitis  patients  with  risk  factors  (duration  of  disease,  extent  of 
inflammation, epithelial dysplasias). A total of 683 paraffin-embedded 
mucosal  biopsies  were  retrospectively  evaluated  for  inflammatory 
activity,  grade of  dysplasia,  ploidy status,  laminin-5 gamma2 chain 
and cyclin A expression. RESULTS: Mild or moderate inflammatory 
activity  was  present  in  78%  of  all  biopsies,  low-  or  high-grade 
dysplasia in 5.5%. There was no difference in inflammatory activity 
and dysplasia between patient groups. In group A, 75% of the biopsies 
exhibited  aneuploid  DNA  distribution  patterns.  Group  B  showed 
mainly  proliferative-diploid  cell  populations  (85%  /  P  =  0.006). 
Laminin-5 gamma2 chain was expressed in 13% of all biopsies, with a 
higher frequency in group A (P = 0.002).  Cyclin A expression was 
found  in  98%  of  all  biopsies,  with  a  higher  number  of  
immunopositive  cells  in  group  A biopsies  (P  =  0.014).  Combined 
nuclear  DNA  assessment,  laminin-5  gamma2  chain  and  cyclin  A 
expression  may  help  to  identify  ulcerative  colitis  patients  with  an 
increased risk for cancer development.
Handa  K,  et,al;  Our  aim  was  to  analyze  the  relationship 
between the proliferative activity of cancer cells, assessed using some 
cell  cycle  markers,  and  clinicopathological  factors  in  colorectal 
carcinoma  patients.  Immunoreactivity  was  evaluated 
semiquantitatively using a scoring system to calculate a staining index 
(SI). The expression of cyclin D1, histone H3 mRNA and cyclin A 
correlated significantly with Ki-67 antigen expression. The SIs of Ki-
67,  cyclin  A  and  histone  H3  mRNA  were  significantly  higher  in 
patients > or = 65 years of age than in those < 65. The SIs of Ki-67 
and  cyclin  D1  in  poorly  differentiated  adenocarcinomas  were 
significantly  higher  than  in  the  other  tumor  types.  The  overall  
survival  was  significantly  lower  in  patients  with  cyclin  A  
overexpression  than  in  those  without.  Multivariate  analysis  
indicated that cyclin A overexpression is an independent prognostic  
factor  in  patients  with  colorectal  adenocarcinoma.  Our  results 
indicate  that  cyclin  D1  overexpression  correlates  with  poor 
adenocarcinoma differentiation and tumor progression, and  cyclin A 
overexpression is a superior indicator of poor prognosis compared  
with the other cell cycle markers tested.
Wang A, et.al; Cyclin E was higher in the cancer tissue than in 
the  non-neoplastic  mucosa  in  92%  patients  (35  out  of  38  cases). 
However, the cyclin A expression of the mucosa was higher than that 
of the cancer tissue in 63% (25 out of 40 cases) cases,  and only 4 
(10%) cancers had higher cyclin A expression. Eleven cancers (27%) 
demonstrated  expression  equivalent  to  that  in  the  mucosa.  Equal 
expression of cyclin D1 in cancer and mucosal tissues was found in 
51% cases (20/39), lower expression of cyclin D1 by cancer tissues 
was  demonstrated  in  41%  cases  (16/39)  and  only  three  cancers 
showed higher expression than the mucosa. Proliferating-cell nuclear 
antigen immunohistochemistry revealed that the labeling index of the 
cancer tissue was 43.5 +/- 8.3% while that of the mucosa was only 
14.8 +/- 5.1%. These results proved that  colorectal cancers express  
high  levels  of  cyclin  E,  consistent  with  a  high  rate  of  cell  
proliferation, whereas most of such cancer lose control of cyclin A  
and  cyclin  D1  expression.
 Bahnassy AA, et,al;  Aberrations in the cell cycle checkpoints have 
been shown to be of prognostic significance in colorectal cancer. The 
expression  of  cyclin  D1,  cyclin  A,  histone  H3  and  Ki-67  was 
examined  in  60  colorectal  cancer  cases  .  Immunoreactivity  was 
evaluated semi quantitatively by determining the staining index of the 
studied proteins. The staining index for Ki-67, cyclin A and D1 was 
higher in large,  poorly differentiated  tumors.  The staining index of 
cyclin  D1  was  significantly  higher  in  cases  with  deeply  invasive 
tumors and nodal metastasis. Overexpression of cyclin A and D1 and 
amplification  of  cyclin  D1  were  associated  with  reduced  overall 
survival.  Multivariate analysis shows that cyclin D1 and A are two 
independent prognostic factors in colorectal cancer patients. Cyclin A 
and D1 are superior  independent  indicators of  poor prognosis  in  
colorectal cancer patients.
2. AIMS & OBJECTIVE
1. Expression of cyclin A in normal rectal mucosa & rectal 
carcinoma
2. Correlation of cyclin A over expression with stage & grade of 
rectal carcinoma.
3. Correlation of cyclin A over expression with response to 
neoadjuvant treatment and recurrence.
3. MATERIAL & METHODS
The  expression  of  cyclin  A  was  evaluated  in  normal  rectal 
mucosa  &  rectal  carcinoma  by  immunohistochemistry  technique. 
Immunoreactivity was evaluated semiquantitively by determining the 
staining index of the studied protein.  
3.1 Patient & tumor details:
Patients with a diagnosis of nonmetastatic rectal carcinoma 
were  considered  for  the  study.  Patients  came  to  cancer  institute 
(WIA) during 2002 to 2003, were prospectively evaluated, treated 
with  protocol  treatment,  re  evaluated,  operated,  treated  with 
adjuvant chemotherapy according to the stage & then followed up.
Punch biopsy was taken from the rectal growth & processed in 
pathology department, paraffin blocks were made & sections were cut 
for  histological  evaluation,  4  micron  thin  sections  were  cut  for 
immunohistochemistry study.
After  complete  evaluation  nonmetastatic  rectal  carcinoma 
patients  who  were  considered  fit  for  protocol  treatment  were 
considered for the study.  Stage grouping of the rectal carcinoma was 
done according to the AJCC cancer staging, 6th edition.
3.2 TNM STAGING:
T Stage:
In situ adenocarcinoma (Tis) includes cancers confined to the 
glandular basement membrane or lamina propria. 
 T1 tumours invade into but not through the submucosa.
T2 tumours invade into but not through the muscularis propria.
T3 tumours invade through the muscularis propria into the 
subserosa or into nonperitonealized pericolic or perirectal tissue.
T4 tumours invade other named organs or structures (T4a) or 
perforate  the  visceral  peritoneum  (T4b).  Tumours  invading  other 
colorectal segments by way of the serosa (i.e., carcinoma of the cecum 
invading the sigmoid) are classified as T4a. A tumor that is adherent 
to other structures or organs macroscopically is classified clinically as 
T4a;  however,  if  the  microscopic  examination  of  the  adhesions  is 
negative, then the pathologic classification is pT3.
N Stage:
A  pN0 designation  may  be  made  even  if  fewer  than  the 
recommended numbers of nodes are present; however, the prognostic 
significance  of this  pN0 designation is  weaker.  N0 denotes that  all 
nodes examined are negative.
N1 includes tumours with metastasis in one to three regional 
lymph nodes.
N2 indicates metastasis in four or more regional lymph nodes. 
Metastatic  nodules  or  foci  found  in  the  pericolic,  perirectal,  or 
adjacent mesentery without evidence of residual lymph node tissue are 
regarded as being equivalent  to a  regional  node metastasis  and are 
counted accordingly. 
M Stage:
M0 disease if no evidence of distant metastases is present. 
M1 disease if distant metastases are present. Involvement of the 
external  iliac,  common  iliac,  para-aortic,  supra-clavicular,  or  other 
non-regional  lymph  nodes  is  classified  as  distant  metastatic  (M1) 
disease. 
Stage grouping: 
Stage I disease is defined as T1 to T2N0 disease in a patient 
without distant metastases (M0). 
Stage  II disease  is  defined  as  T3  to  T4N0M0.   T3N0  is 
classified as stage IIA and T4N0 is classified as stage IIB. 
Stage III disease is defined node positivity in the absence of 
M1  disease.  The  current  TNM  staging  system  stratifies  stage  III 
disease into
IIIA --T1 to T2N1.
IIIB --T3 to T4N1.
IIIC--Any T, N2. 
Stage IV disease is defined as metastatic disease. 
3.3 Histological Grade: 
The tumours were graded into 
grade 1--well differentiated.              grade 3--poorly differentiated. 
grade 2--moderately differentiated.  grade 4--undifferentiated.
3.4 Protocol treatment:
Protocol  treatment  comprises  of  neoadjuvant  concurrent  two 
cycles of chemotherapy (5 fluorouracil  & mitomycin  C) & 50 gray 
external beam radiotherapy to the pelvis. One month after completion 
of  protocol  treatment  patients  were  reassessed  &  taken  up  for 
operative procedure (anterior resection /abdomino- perineal resection). 
The  specimens  were  examined  & histopathological  evaluation  was 
done.  Biopsies  from normal  rectal  mucosa  and  rectal  growth were 
taken for immunhistochemistry study.
3.5 Immunohistochemistry procedure:
3.51 Slide preparation:
The paraffin embedded sections of 4 micron size were placed 
on  APES  coated  slides.  The  slides  were  treated  in  xylene 
consecutively twice for 8 minute each for dewaxing of the sections. 
This was followed by treatment in100% alcohol consecutively twice 
for dehydration for one minute each .The slides were washed in tap 
water for 8 minutes, taking care not to disturb the sections. Followed 
by tap water wash, the slides were placed in 0.3 % hydrogen peroxide 
for 30 minutes to quench the endogenous peroxidase activity in the 
tissues.
3.52 Antigen retrieval: 
For the protein involved in the study needed antigen retrieval to 
expose the epitopes for immune reaction. Antigen retrieval was done 
by  placing  the  slides  dipped  in  1mM  EDTA  solution  at  pH  8  in 
autoclave at 121 degree centigrade, 15 pound pressure for 0 minute 
holding time.  After  antigen retrieval the slides were cooled & than 
washed with fresh PBS solution for 5 minutes.
3.53 Blocking & antibody reaction: 
The slides were arranged in a moist chamber to prevent drying 
of  the sections & 100 Micro liter  of 3 % BSA was added to each 
section, taking care to cover the whole section &than left undisturbed 
for  30 minutes.  Following gentle tipping & drying of BSA off  the 
slides the primary antibody (75 micro liter) in appropriate dilutions 
(1:50) was added to each section. Care was taken to omit the negative 
control.  They  were  left  for  45  minutes  to  incubate  with  primary 
antibody (cyclin A) at room temperature. The slides were washed with 
fresh PBS thrice for 5 minutes each to wash the excess of primary 
antibody. Secondary antibody (Anti cyclin A antibody, 75 micro liter) 
was added in appropriate dilutions (1:500 in 3% BSA) to each slide & 
incubated for 30 minutes. The slides were washed in PBS thrice for 5 
minutes each followed by drying & addition of fresh ABC complex 
(75 micro liter) onto each slide and incubated for 30 minute at room 
temperature. 
ABC solution is made by 9 microliter of Avidin & 9 micro liter 
of biotin mixed in 982 microliter of fresh PBS.
3.54 Treatment with chromogen: 
The slides were washed in PBS thrice for  5 minutes each to 
wash the excess of ABC and the slides were treated in a solution of 
DAB (150 ml of water + 150 ml of PBS + 100 micro liter of hydrogen 
peroxide + 150ml of DAB) for 5 minutes. The excess of DAB was 
washed  off  by  keeping the slides  in  tap  water  for  10 minutes  and 
counter stained in haematoxylene for 2 minutes. Followed by water 
wash  for  10  minutes.  The  slides  were  fixed  in  lithium  carbonate 
saturated  solution  and  washed  under  tap  water  once  again  for  10 
minutes. The slides were drained well and treated with 100 % ethanol 
twice for 30 seconds each. This was followed by treatment in xylene 
consecutively for  5 minutes  each and sections  were mounted using 
DPX.
3.55 Statistical procedure: 
The results of the immunohistochemical study were examined 
for correlation of cyclin A over expression with clinico-pathological 
parameters using the Chi square test for contingency tables.
3.56 Photographs
PHOTOGRAPH 1
This photograph is of invasive carcinoma of cervix. 
Positive Control Slide The  brown  nuclei  in  the 





This  photograph  is  of  rectal  carcinoma,  the  brown  nuclei 
denotes cyclin A over expression. 
PHOTOGRAPH 4
Signet  ring  cell  carcinoma  with  very  low  cyclin  A  over 
expression.
4.  RESULTS & DISCUSSION









Nil 0 4 (19%)
<10% 3 (14.4%) 0
>10% 0 14 (66.6%)
Nuclear cyclin A expression was less then 10% in normal rectal 
mucosa. Nuclear cyclin A expression was not seen in 19% of rectal 
carcinoma. Nuclear cyclin  A over expression (i.e.>10%) was seen in 
66.6% of rectal carcinoma.
4.2 The age & sex distribution:
Table 4
          83.3% of the rectal carcinoma patients are male & 16.7% 
are female. The age distribution in male are 44.4% patient was in 
age group of 41 to 60 year, 16.5% in age group of 61-80% & 
22.2% in age group of 21-40 years. Amongst females 11% were 
of age group 41-60year 5.55% in age group of 21-40 years.
4.3  Distribution  of  rectal  cases  carcinoma according  to 
histology  type: 
Table 5
Histologic type No of cases 18=100%







Adenocarcinoma of rectum constitutes 66.6% of cases, 22.2% 
case were mucin secreting adenocarcinoma & 11.1% were signet ring 
cell carcinoma.
4.4  Distribution  of  rectal  carcinoma  according  to 
nuclear grade:                         
                                 Table 6




77.7% of rectal carcinoma were nuclear grade II, followed by 
16.6% grade III & 5.5% grade I.
4.5 Distribution of rectal carcinoma according to primary 
tumor stage:                                         
Table 7
T stage No. of cases(Total=18) % (18=100%)
T 1 0 0
T 2 1 5.5
T 3 13 72.2
T 4 4 22.2
72.2%  of  rectal  carcinoma  was  in  T3  primary  tumor  stage, 
22.2% in T4 & 5.5% in T2 primary tumor stage.
4.6 Distribution of rectal carcinoma according to 
recurrence: 
Table 8
Recurrence No. of cases( 18 ) 18=100%
present 7 38.9%
No rec. 11 61.1%
The follow up duration of patients ranged from 7 month to 44 
month, 38.95 of patients developed recurrence.
4.7 Response to neoadjuvant protocal treatment: 
Table 9
Response No. of cases 18=100%
Complete 3 16.7
Partial 15 83.3
In  83.3% of  carcinoma  rectum patients  partial  response  was 
achieved, & 16.7% of patients complete response was achieved.
4.8 Status of cyclin A over expression in rectal carcinoma: 
Table 10
Cyclin A over expression No. of cases (18) 18=100%
Absent 4 22.2
Present 14 77.7
77.7% of rectal carcinoma patients over expressed cyclin A & 
22.2% cases did not express cyclin A.
4.9 Correlation of age & cyclin A expression:
Table 9
        Age
       years
Cyclin A over expression
Present (%)                                      Absent
0-20 0                                                          0
21-40 4       (80%)                                         1(20%)
41-60 7      (70%)                                          3(30%)
61-80 3     (100%)                                         0
81-100 0                                                          0
4.10 Correlation of histologic type & cyclin A 
over expression: 
                                        Table 10
Histologic   type
Cyclin A over expression( 18 cases )
Present(%)                         Absent(%)
Adenocarcinoma-12, cases 10    (83.3)                              2( 16.7)
Mucin secreting-4,cases 3     (75)                                  1(25)
Signet ring cell-2,cases 1      (50)                                1(50)
The over expression of cyclin A in adenocarcinoma is 83.3%, in 
mucin secreting carcinoma is 75% & in signet ring cell carcinoma is 
50%.





Cyclin A over expression
Present (%)                            Absent(%)
14 cases                                     4 cases
1 0                                                1(100%)
2 12 (85.7%)                                2(14.3%)
3 2   (66.6%)                                1(33.4%)
4 0                                                0
pValue: 0.23
Nuclear  grade  I  rectal  carcinoma  did  not  express  cyclin  A. 
Nuclear  grade II rectal  carcinoma,  85.7% over expressed cyclin A. 
Nuclear grade III rectal carcinoma, 66.6% over expressed cyclin A. 
Cyclin A over expression is more in high grade carcinomas.
4.12 Correlation of primary tumor stage & 




Cyclin A over expression
Present (%)                             Absent(%)
14 cases                                   4 cases
T1     0, case  0                                                  0
T2     1 1 (100%)                                      0
T3    13 9 (69.2%)                                    4(30.8%)
T4    4 4 (100%)                                     0
pValue: 0.37
The primary tumor stage T2, 100% of patients over expressed 
cyclin A, as the number of cases are less correlation b/w T2 & cyclin 
A over expression may not right.
Primary tumor stage T3 the cyclin A over expression was seen 
in 69.2% & stage T4 the cyclin A over expression was seen in 100%. 
4.13 Correlation of response to neo-adjuvant treatment 




Cyclin A over expression
Present (%)                              Absent(%)
14 cases                                   4 cases
Complete response 3,cases 2(66.6)                                    1(33.4%)
Partial response 15,cases 12(80%)                                  3(20%)
pValue: 0.79
80% of partial responders to neoadjuvant chemo-radiotherapy & 
66% of complete responders to the neoadjuvant chemo-radiotherapy 
were over expressing cyclin A.
4.14 Correlation between recurrence & cyclin A over 
expression: 
                                    Table 16
Recurrence
18 cases
Cyclin A over expression
Present (%)                    Absent(%)
14 cases                           4 cases
Present 7,cases 4(28.6)                                3(75)
Absent 11,cases 10(71.4)                              1(25)
pValue: 0.14
Patients  who  recurred  after  complete  treatment  28.6%  over 
expressed cyclin A, whereas patients who did not recur the cyclin a 
over expression was seen in 71.4%
5. DISCUSSION
In this study Cyclin A over expression is studied in normal 
rectal  mucosa  and rectal  carcinoma.   The normal  rectal  mucosal 
expression of cyclin A is very less (14.4 %), when compared with 
over expression of cyclin A in rectal carcinoma (66.6 %).  In the 
study  done  by  Li.  J.Q  et  al.,  Cyclin  A  expression  gradually 
increased  from  mild  through  moderate  to  severe  dysplasia  in 
adenomas and from normal tissue through hyperplasia to adenoma 
to early carcinoma indicating that  over expression is  a relatively 
early event in colon carcinogenesis which is possibly responsible 
for  the  pathological  changes  in  the  mucosa  preceding neoplastic 
transformation.   More  recently  Bahanassy  et  al.,  Handa  et  al., 
Habermann  et  al.,  Nozoe  et  al.,  and  Bondi  et  al.,  reported  up 
regulation of cyclin A in 80%, 70%, 68%, 61% and 83% of their 
studied cases.
Cyclin A over expression is also reported in carcinoma of 
the breast by Buckholm IR etal, and cervix by  Shiohara S etal & 
Vijayalakshmi etal.
Cyclin  A is  over  expressed  in  carcinoma  because  large 
fraction of carcinomatous  cells are in cell cycle phases.
Cyclin A over expression varies with the histological type. 
In  our  study,  the  cyclin  A  over  expression  is  more  in 
adenocarcinoma than mucin secreting adenocarcinoma and least 
in signet ring cell carcinoma.  The study done by Li.JQ etal,  they 
inferred that cyclin A over expression significantly decreased in 
mucinous  type  of  colorectal  adenocarcinoma.   The  decreased 
expression  of  cyclin  A  in  mucinous  and  signet  ring  cell 
carcinoma may  be  due  to  presence  of  mucin  which interferes 
with the immunoreaction.  It  needs a detailed study in a large 
number of cases and a correlative study to know the cause & its 
implications as prognostic and predictive markers.
In our study, the Cyclin A over expression in nuclear grade 
2, 3 are 85.7%, 66.6% respectively.  The nuclear grade 1 tumor 
did  not  express  Cyclin  A.  Higher  the  nuclear  grade  the 
probability of cyclin A over expression is also more.  Higher the 
nuclear grade the more the tumor is poorly differentiated hence 
more fraction of cells are in cell cycle phase & more expression 
of  cell  cycle  markers.   Bahanassy  etal   also  concluded in  his 
study that as the grade of primary tumor increases the cyclin A 
over expression increases.  
The cyclin A over expression in correlation with primary 
tumor stage does not show any increasing & decreasing trend.  It 
may be because as the primary tumor stage increases the size of 
the tumor also increases and more fraction of carcinoma cells are 
in the resting phase of  the cell cycle these cells does not over 
expression cyclin A. It also depends from which site the sections 
are taken from the tumour. In the study done by  Li.JQ et al they 
concluded  that  cyclin  A  over  expression  was  significantly 
decreased in the advanced stage tumor,  whereas Bhanassy etal 
concluded  that  staining  index  for  cyclin  A over  expression  is 
higher in large tumours.
Cyclin  A  over  expression  in  partial  responders  to 
neoadjuvant  treatment  is  80%  and  in  complete  responders  is 
66.6%.  The Cyclin A over expression presence or absence does 
not  correlate  with  the  response  to  neoadjuvant  treatment.   It 
needs further detailed study in large number of patients to come 
on a definitive conclusion.
In our study patients with over expression of cyclin A in 
rectal carcinoma 71.1% did not recur and patients with absence 
of  Cyclin  A over  expression  developed  recurrence  in  75% of 
cases.   Bondi  etal  also  concluded  in  his  study  that  over 
expression  of  cyclin  A  was  independently  associated  with  a 
better out come in colonic adenocarcinoma.  
In the patients who developed recurrence after  complete 
treatment the correlation of the presence & absence of cyclin A 
over expression does not show a trend, this may be because the 
recurrence of carcinoma also depends upon the completeness of 
resection of the carcinoma with a safe margin.  
The  number  of  patients  &  duration  of  followup  in  the 
present study is less.  The duration of followup ranged between 7 
to 44 months & only seven patients came for followup for more 
than 24months. Nine patients were lost to followup.
                      
6. CONCLUSION
Cyclin A expression is seen in normal rectal mucosa & it is over 
expressed in rectal carcinoma.
Cyclin  A  over  expression  is  less  in  mucin  secreting 
adenocarcinoma & signet ring cell carcinoma of rectum in comparison 
to adeno carcinoma of rectum.
The over expression of cyclin A is more in higher grade rectal 
carcinoma. 
As the primary tumor stage of rectal carcinoma increases the 
over expression of cyclin A also increases.
Presence  or  absence  of  cyclin  A  over  expression  does  not 
correlate response to neoadjuvant treatment. 
The  correlation  of  recurrence  of  the  rectal  carcinoma  after 
neoadjuvant chemo-radiotherapy followed by surgery & cyclin A over 
expression needs further evaluation in a large number of patients with 
a longer duration of follow up to come to a definitive conclusion.
7.  REFERENCES
Aaltomaa S, Lipponen p, Ala-opas M et al., Expression 
of cyclin A,  D and p21 proteins on renal cell  cancer and 
their  related  to  clinico-pathological  variables  and patient 
survival. Brit. J. cancer 80; 2001-2007,1999.
 Bahnassy  AA,  Zekri  AR,  El-Houssini  S,  El-Shehaby 
AM, Mahmoud MR, Abdallah S, El-Serafi M. Cyclin A and 
cyclin  D1 as significant  prognostic markers in colorectal 
cancer patients. BMC Gastroenterol. 2004 Sep 23;4(1):22.
Bernard  W,  Stewart  Paulo,   Kleihues;  WHO  ;  World  cancer  report 
198:2003.
Bondi  J,  Husdal  A,  Bukholm  G,  Nesland  JM,  Bakka  A, 
Bukholm IR. Expression and gene amplification of primary (A, B1, 
D1,  D3,  and  E)  and  secondary  (C  and  H)  cyclins  in  colon 
adenocarcinomas and correlation with patient outcome.: J Clin Pathol. 
2005 May;58(5):509-14.
Brown  MO,  Lanier  AP,  Becker  TM;  Colorectal  cancer 
incidence  and  survival  among  Alaska  natives,  1969-1993.  Int   J 
Epidemiol 1998;27:388.
Bukholm IR, Bukholm G, Holm R, Nesland JM. Association 
between histology grade,  expression of  HsMCM2,  and cyclin  A in 
human  invasive  breast  carcinomas.  J  Clin  Pathol.  2003 
May;56(5):368-73.
Chem J, Stampper MJ, Hough HL etal. A prospective studies of 
N.acetyl transferase genotype, red meat intake, & risk of colorectal 
cancer. Cancer Res 1998;58:3307.
Compton cc, Fielding LP,. Burgart LJ, et al. Prognostic factors 
in  colorectal  cancer.  College  of   American  pathologist   consensus 
statement 1999. Arch    Pathol Lab Med 2000;124:979.
Draetta G ,  Piwnica WS,  Morrinson D et al.  Human CDC2 
protein    kinase  is  a  major  cell  cycle  regulated   tyrosine  kinase 
substrate. Nature,336;738-740,1988.
Dutta V, Less E & Reed SI.  Association of human cyclin E 
with  a  periodic  G1-S  phase  protein  kinase   Science  (  Washington 
DC ), 257: 1958-1961,1992.
Fuchs CS , Giovannucci EL , Colditz Ga, et al. A prospective 
study of family history and the risk of colorectal cancer. NEJM 1994; 
331:1669.
GLOBOCON.2000; IARC.
Glotzer M, Murray AW and Kirchner MW. Cyclin is regulated 
by the ubiquitin pathway. Nature,349.132-134,1991.
 Guadagno TM, Ohtsubom , Roberts JM, et al . A link between 
cyclin  A expression and adhesion dependent  cell  cycle  progression 
science 262; 1572-1574,1993.
Habermann J, Lenander C, Roblick UJ, Kruger S, Ludwig D, 
Alaiya  A,  Freitag  S,  Dumbgen  L,  Bruch  HP,  Stange  E,  Salo  S, 
Tryggvason K, Auer G, Schimmelpenning H. Ulcerative colitis and 
colorectal  carcinoma:  DNA-profile,  laminin-5  gamma2  chain  and 
cyclin  A expression  as  early  markers  for  risk  assessment.  Scand J 
Gastroenterol. 2001 Jul;36(7):751-8.
Hamaguchi JR, Tobey RA, Pines j, et al. Requirement of p34 
CDC2 kinase is restricted to mitosis in the mammalian CDC@ mutant 
FT210.J.Cell BIOL:117: 1041-1053 ;1992.
Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi  T. 
Expression of cell cycle markers in colorectal carcinoma: superiority 
of cyclin A as an indicator of poor prognosis. Int J Cancer. 1999 Jun 
21;84(3):225-33.
Hunt  T,  Cyclins  and  their  partner  from  A  single  idea  to 
complicated reality. Semin. Cell. Biol;2:213-219.1991.
Hunt  T,  Luca  FC  and  Ruderman  JV.  The  requirements  for 
protein synthesis  and degradation and the control  of  destruction of 
cyclins  A and  B in  the  meiotic  & mitotic  cell  cycles  of  the  clam 
embryo. J .Cell Biol,116:707-711,1992.
Inaba  J,  Matsushime  H,  Valentune  M,  et  al.  Genomic 
organization, chromosomal localisation and independent expression of 
human cyclin D genes.  Genomic, 13 : 565-574, 1992.
Li JQ, Miki H, Wu F, Saoo K, Nishioka M, Ohmori M, Imaida 
K.  Cyclin  A  correlates  with  carcinogenesis  and  metastasis,  and 
p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. 
Hum Pathol. 2002 Oct;33(10):1006-15.
Morgan  DO,  Cyclin  dependent  kinases;  Engines,  clocks  & 
micro-processor. Annul . Rev. Cell. Dev. Biol;13:261-91:1997.
      Nozoe  T,  Inutsuka  S,  Honda  M  ,  Clinico-pathologic 
significance of cyclin A expression in colorectal carcinoma. J. Exp. 
Clinic. Cancer Res.2004 Mar; 23(1):127-33. 
Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in 
mammalian fibroblasts. Science 1993;259:1908. 
Pagano M, Peeperkok R, Verde F, et al., Cyclin A is required at 
two points in the human cell cycle. EMBO J.11: 961-966, 1992.
Palozza P, Serini S, Maggiano N, Angelini M, Boninsegna A, 
Di Nicuolo F, Ranelletti FO, Calviello G. Induction of cell cycle arrest 
and  apoptosis  in  human  colon  adenocarcinoma  cell  lines  by  beta-
carotene  through  down-regulation  of  cyclin  A  and  Bcl-2  family 
proteins. Carcinogenesis. 2002 Jan;23(1):11-8
Parkin  DM,  Pisani  P,  Ferlay  J.  Global  cancer  statistics.  Ca. 
Cancer J Cin 1999;49:33.
Peter M, Nakagawa J, Dorce M, et al,  In vitro disassembly of 
the nuclear lamina and M phase specific phosphorylation of lamins by 
cdc2 kinase: Cell , 61 ; 591-599, 1990.
 Peters L, Stern. Immunity to human papilloma virus associated 
cervical neoplasia.  Adv. In Cancer Res. 69 ; 175-177,1996.
Presti  JC,  Reuter  VE,   Galan  T,  etal.  Molecular  genetic 
alterations in superficial and locally advanced human bladder cancer. 
Cancer Res, 51; 5405-5409, 1991.
Rechsteiner M and Rogers SE, PEST sequences and  regulation 
by proteolysis. TiBS, 21: 267-271;1996. 
Resnitzky D, Gossen M, Bujard H, et al.  Acceleration of the 
G1/S  phase  transition  by  expression  of  cyclins  D1  and  E with  an 
inducible system. Mol Cell Biol 1994;14:1669.  
Seitz HK, Simanowski UA,  Garzon FT, et al. Possible role of a 
acetaldehyde  in  ethanol  rectal  carcinogenesis  in  the  rat 
.Gastroenterology 1990;98:406.
Sherr J, Cancer Cell Cycles. Science, 274: 1672-1677; 1996.
Shiohara S, Shiozawa T, Miyamoto T, Feng YZ, Kashima H, 
Kurai M, Suzuki A, Konishi I. Expression of cyclins, p53, and Ki-67 
in cervical squamous cell carcinomas: over expression of cyclin A is a 
poor prognostic factor in stage Ib and II disease. Virchows Arch. 2005 
May 13; [Epub ahead of print]
Singh PN, Fraser GE : Dietary risk factors for colon cancer in 
alow risk population. Am. J. Epidemiology, 1998 : 148, 761.
Smalley  W,  Ray  WA,  Daugherty  J  ,  Use  of  NSAIDs  and 
incidence of colo-rectal cancer, a population based study . Arc. Intern. 
Medicine . 1991; 159,161.
Stevens  C,  La  Thangue  NB.  E2F  and  cell  cycle  control:  a 
double-edged sword. Arch Biochem Biophys 2003;412:157. 
Stiegler P, Giordano A. The family of retinoblastoma proteins. 
Crit Rev Eukaryot Gene Expr 2001;11:59.  
          Tsai LH,  Haslow E, Meyerson M, et al; Isolation of human 
CDK2 gene that encodes the cyclin A and adenovirus EIA associated 
p53 kinase. Natur, 353: 174-177, 1991.
Vrede F, Dogerteom M, Stelzer E, et al, Control of microtubule 
dynamics  and length  by cyclin  A & cyclin  B dependent  kinase  in 
xenopus egg extracts. J.Cell.Biol ,118 :pp. 1097-1099, 1992.
          Vijayalakshmi. N, Rajkumar T, et al. Cell cycle regulatory 
molecues  in  normal,  dysplastic  &  malignant  cervical  epithelium. 
THESIS.
Wang A, Yoshimi N, Suzui M, Yamauchi A, Tarao M, Mori H. 
Different  expression  patterns  of  cyclins  A,  D1  and  E  in  human 
colorectal cancer. J Cancer Res Clin Oncol. 1996;122(2):122-6.
          Xiong Y, Menninger J, Beach D et al; Molecular cloning and 
chromosomal  mapping  of  CCND genes  encoding  human D –  type 
cyclins. Genomics,13; 575-584;1996.
          Yamamato  M,  Yoshida  M,  Onok et  al.  Effect  of  tumor 
suppressors on cell cycle regulatory genes. RB suppresses p34 cck2 
expression  and  normal  p53  suppresses  cyclin  A  expression.  Exp. 
Cell :Res.210; 94 –101,1994.
